HPV vaccine push in schools could cut cancer risk for south african kids

NCT ID NCT05919901

Terminated Prevention Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a school-based communication strategy to help more children aged 9-12 in South Africa get the HPV vaccine, which prevents cancers caused by HPV. The program involves health materials and vaccine provision in schools. Researchers will measure how many children start and complete the vaccine series, aiming to reach those often missed by traditional healthcare.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine
What this could lead to: If successful, this approach could increase HPV vaccination rates in vulnerable communities, potentially reducing cervical cancer risk.
What could go wrong: The trial is suspended, and it is a small early-stage feasibility study. Results may not apply broadly, and the intervention may not improve uptake as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV

Contacts and locations

Locations

University of Witwatersrand Health Consortium

Johannesburg, Gautang, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.